Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study

Espitia-Hernandez et al., Biomedical Research, 31:5, Aug 2020
Recovery time 70% improvement lower risk ← → higher risk Viral+ at day 10 97% primary Ivermectin  Espitia-Hernandez et al.  EARLY TREATMENT Is early treatment with ivermectin + combined treatments beneficial? Retrospective 35 patients in Mexico Faster recovery (p=0.0001) and improved viral clearance (p<0.0001) c19early.org Espitia-Hernandez et al., Biomedical R.., Aug 2020 0 0.5 1 1.5 2+ RR
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 106 studies, recognized in 24 countries.
Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
6,300+ studies for 210+ treatments. c19early.org
Meta Analysis
Small study with 28 patients treated with ivermectin + AZ + cholecalciferol and 7 control patients.
All treated patients were PCR- at day 10 while all control patients remained PCR+. The mean duration of symptoms was 3 days in the treatment group and 10 days in the control group.
This is the 3rd of 106 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001.
53 studies are RCTs, which show efficacy with p=0.000000087.
Important missing comments or errors? Let us know.
Study covers vitamin D and ivermectin.
recovery time, 70.0% lower, relative time 0.30, p < 0.001, treatment 28, control 7.
risk of viral+ at day 10, 97.2% lower, RR 0.03, p < 0.001, treatment 0 of 28 (0.0%), control 7 of 7 (100.0%), NNT 1.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Espitia-Hernandez et al., 15 Aug 2020, retrospective, Mexico, peer-reviewed, mean age 45.1, 5 authors, dosage 6mg days 1-2, 8-9, this trial uses multiple treatments in the treatment arm (combined with azithromycin and cholecalciferol) - results of individual treatments may vary.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org January 2026 Mexico United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Peru Philippines Vietnam Spain Brazil Italy France Japan China Uzbekistan Nepal Ethiopia Iran Ghana South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Mongolia Czechia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR Mexico favored high-profit treatments.The average efficacy of treatments was moderate.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org January 2026 Mexico United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Peru Philippines Vietnam Spain Brazil Italy France Japan China Uzbekistan Nepal Ethiopia Iran South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Ukraine Bulgaria Greece Slovakia Singapore Mongolia Czechia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia Syria Mexico favored high-profit treatments.The average efficacy was moderate.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study
References
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Choudhary, Sharma, Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance, Microbes Infect
Damle, Vourvahis, Wang, Leaney, Corrigan, Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19, Clin Pharmacol Ther
Dasgupta, Sen, Bakshi, Dasgupta, Manna et al., Nsp7 and Spike Glycoprotein of SARS-CoV-2 are envisaged as Potential Targets of Vitamin D and Ivermectin
Derendorfhjijoaa, Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin
Hribar, Cobbold, Church, Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson's disease, Brain Sciences
Ilie, Stefanescu, Smith, The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality, Aging ClinExp Res
Kirchdoerfer, Ward, Structure of the SARS-CoV NSP12 polymerase bound to NSP7 and NSP8 co-factors2019, Nat commun
Lauer, Grantz, Bi, Jones, Zheng et al., The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application, Ann Intern Med
Lee, Park, Kwon, Ham, Kim et al., Decreased lung function is associated with elevated ferritin but not iron or transferrin saturation in 42,927 healthy Korean men: A cross-sectional study, PLOS ONE
Sohrabi, Alsafi, Neill, Khan, Kerwan et al., World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19), Int J Surg
Sun, Lu, Xu, Sun, Bjjomv, Understanding of COVID-19 based on current evidence
Ulrich, Pillat, CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement, Stem Cell Rev Rep
Xydakis, Dehgani-Mobaraki, Holbrook, Geisthoff, Bauer et al., Smell and taste dysfunction in patients with COVID-19, Lancet Infect Dis
Zheng, Yang, Hu, Li, Wang et al., Vitamin D attenuates lung injury via stimulating epithelial repair, reducing epithelial cell apoptosis and inhibits TGF-β induced epithelial to mesenchymal transition, Biochem Pharmacol
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0